

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES**

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Scripture Charity</u> (Last) (First) (Middle) C/O BELLICUM PHARMACEUTICALS, INC. 3730 KIRBY DRIVE, SUITE 1200 (Street) HOUSTON TX 77098 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 12/01/2021	3. Issuer Name and Ticker or Trading Symbol <u>BELLICUM PHARMACEUTICALS, INC [BLCM]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) _____ <u>Chief Development Officer</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	14,587	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (right to buy)	(1)	11/01/2028	Common Stock	2,500	4.41	D	
Stock Option (right to buy)	(2)	02/02/2030	Common Stock	19,300	1.36	D	
Stock Option (right to buy)	(3)	08/02/2030	Common Stock	20,000	7.13	D	
Stock Option (right to buy)	(4)	12/14/2030	Common Stock	35,000	2.97	D	
Stock Option (right to buy)	(5)	08/16/2031	Common Stock	50,000	2.88	D	

Explanation of Responses:

- 25% of the shares subject to the stock option vest and became exercisable on October 1, 2019, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
- 25% of the shares subject to the stock option vest and became exercisable on February 3, 2021, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
- 100% of the shares subject to the stock option vest and became exercisable on August 3, 2021.
- 50% of the shares subject to the stock option vest and become exercisable on December 15, 2021, and the remaining shares subject to the stock option vest and become exercisable in 12 equal monthly installments thereafter.
- 50% of the shares subject to the stock option vest and become exercisable on August 16, 2022, and the remaining shares subject to the stock option vest and become exercisable in 12 equal monthly installments thereafter.

Remarks:

Charity Scripture

12/02/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.